Kevin Krause
Corporate Officer/Principal en AN2 THERAPEUTICS, INC. .
Fortuna: 103 721 $ al 31/03/2024
Perfil
Kevin Krause is currently the Chief Strategy Officer at AN2 Therapeutics, Inc. He previously worked as the Senior Director-Corporate Development at Achaogen, Inc. from 2015 to 2019 and as a Member-Clinical Microbiology at Cerexa, Inc. from 2010 to 2014.
He received an undergraduate degree from San Francisco State University and an MBA from Haas School of Business.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
AN2 THERAPEUTICS, INC.
0.11% | 15/03/2024 | 31 914 ( 0.11% ) | 103 721 $ | 31/03/2024 |
Cargos activos de Kevin Krause
| Empresas | Cargo | Inicio |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Corporate Officer/Principal | 01/08/2021 |
Antiguos cargos conocidos de Kevin Krause.
| Empresas | Cargo | Fin |
|---|---|---|
| ACHAOGEN | Corporate Officer/Principal | 01/06/2019 |
Cerexa, Inc.
 Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Corporate Officer/Principal | 01/12/2014 |
Formación de Kevin Krause.
| San Francisco State University | Undergraduate Degree |
| Haas School of Business | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| AN2 THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Kevin Krause
